MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

SAN DIEGO -- Pirtobrutinib (Jaypirca) delayed disease progression versus other available options in patients with chronic lymphocytic leukemia (CLL) who had previously received a covalent Bruton's ...

Fixed-duration Venclexta/Gazyva or Venclexta/Imbruvica therapies show noninferior progression-free survival compared to continuous Imbruvica in untreated CLL patients. Three-year progression-free ...

For patients who have chronic lymphocytic leukemia (CLL), experiencing Richter transformation with central nervous system ...

Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic lymphocytic leukemia, according to an analysis. A recent study highlights the ...

Nurix Therapeutics (NRIX) stock: bexobrutideg’s BTK degradation shows strong efficacy in B-cell cancers, backed by $650M cash ...

Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...

Jaypirca showed superior PFS and lower discontinuation rates compared to standard treatments in CLL/SLL patients. Jaypirca reduced the risk of progression or death by 46% to 52% and had a favorable ...

The risk reduction observed in BRUIN CLL-313 is among the most compelling observed for a single agent BTK inhibitor in a front-line CLL study These data will be simultaneously published in the Journal ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...